Secukinumab significantly improves disease severity and patient-reported outcomes up to 1 year of follow-up: Real-world analyses from the Corrona Psoriasis Registry - 22/08/19
Jerry Bagel, MD, Psoriasis Treatment Center of Central New Jersey, East Windsor, NJ; Rebecca Germino, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ’ Adriana Guana, MD, LEO Pharma US, Madison, NJ; Vivian Herrera, DDS, MPH, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Jeffrey D. Greenberg, MD, MPH, Corrona, LLC, Waltham, MA and New York University School of Medicine, New York, NY; Heather J. Litman, PhD, Corrona, LLC, Waltham, MA; Ning Guo, MS, Corrona, LLC, Waltham, MA; Mark Lebwohl, MD, Icahn School of Medicine at Mount Sinai, New York, NY; Bruce E. Strober, MD, PhD, University of Connecticut Health Center, Farmington, CT and Probity Medical Research, Waterloo, Ontario, Canada
Le texte complet de cet article est disponible en PDF.| The Corrona Psoriasis Registry is sponsored by Corrona, LLC, and is funded by AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly and Company, Merck, Novartis Pharmaceuticals Corporation, and Valeant. |
Vol 81 - N° 4S1
P. AB122 - octobre 2019 Retour au numéro
Article précédent
- Secukinumab demonstrates significant improvement of disease activity and health-related quality of life at 1 year in Canadian psoriasis patients in a real world setting
- Sentinel lymph node biopsy in Merkel cell carcinoma: Predictors of sentinel lymph node utilization, positivity and effects on overall survival
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?